Header Logo

Connection

Michael Horberg to Anti-HIV Agents

Back to Details
This is a "connection" page, showing publications Michael Horberg has written about Anti-HIV Agents.
Michael Horberg
Connection Strength
6.842
Anti-HIV Agents
  1. Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system. HIV Clin Trials. 2018 10; 19(5):177-187.
    View in: PubMed
    Score: 0.574
  2. The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDS. 2015 Nov; 29(11):582-90.
    View in: PubMed
    Score: 0.467
  3. Getting to normal: are we there yet? AIDS. 2013 Mar 27; 27(6):1027-8.
    View in: PubMed
    Score: 0.390
  4. Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance. Am J Prev Med. 2013 Jan; 44(1 Suppl 2):S125-8.
    View in: PubMed
    Score: 0.384
  5. Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2012 Jun 01; 60(2):183-90.
    View in: PubMed
    Score: 0.368
  6. Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia. AIDS Patient Care STDS. 2012 May; 26(5):253-5.
    View in: PubMed
    Score: 0.363
  7. Syphilis epidemiology and clinical outcomes in HIV-infected and HIV-uninfected patients in Kaiser Permanente Northern California. Sex Transm Dis. 2010 Jan; 37(1):53-8.
    View in: PubMed
    Score: 0.312
  8. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010 Jan; 53(1):62-9.
    View in: PubMed
    Score: 0.312
  9. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr. 2009 Aug 01; 51(4):367-73.
    View in: PubMed
    Score: 0.303
  10. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. 2009 Mar 03; 150(5):301-13.
    View in: PubMed
    Score: 0.294
  11. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
    View in: PubMed
    Score: 0.287
  12. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 2008 Apr; 22(4):301-12.
    View in: PubMed
    Score: 0.276
  13. Fracture Risk and Association With TDF Use Among People With HIV in Large Integrated Health Systems. J Acquir Immune Defic Syndr. 2023 12 01; 94(4):341-348.
    View in: PubMed
    Score: 0.204
  14. Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study. Lancet HIV. 2022 03; 9 Suppl 1:S2.
    View in: PubMed
    Score: 0.181
  15. Clinic-Level Factors Associated With Time to Antiretroviral Initiation and Viral Suppression in a Large, Urban Cohort. Clin Infect Dis. 2020 10 23; 71(7):e151-e158.
    View in: PubMed
    Score: 0.165
  16. A Flow-Based Model of the HIV Care Continuum in the United States. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):548-553.
    View in: PubMed
    Score: 0.132
  17. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr. 2017 08 01; 75(4):382-390.
    View in: PubMed
    Score: 0.132
  18. Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients. J Am Heart Assoc. 2017 Apr 24; 6(4).
    View in: PubMed
    Score: 0.129
  19. Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. AIDS Patient Care STDS. 2017 Mar; 31(3):129-144.
    View in: PubMed
    Score: 0.128
  20. Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment. J Acquir Immune Defic Syndr. 2016 10 01; 73(2):197-204.
    View in: PubMed
    Score: 0.124
  21. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defic Syndr. 2016 Apr 01; 71(4):413-9.
    View in: PubMed
    Score: 0.120
  22. Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016 Jan; 32(1):50-8.
    View in: PubMed
    Score: 0.116
  23. Missed office visits and risk of mortality among HIV-infected subjects in a large healthcare system in the United States. AIDS Patient Care STDS. 2013 Aug; 27(8):442-9.
    View in: PubMed
    Score: 0.100
  24. Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis. 2013 Apr; 56(8):1174-82.
    View in: PubMed
    Score: 0.096
  25. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
    View in: PubMed
    Score: 0.095
  26. The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):321-7.
    View in: PubMed
    Score: 0.093
  27. Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis. 2011 Sep 15; 204(6):893-901.
    View in: PubMed
    Score: 0.088
  28. Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. Am J Epidemiol. 2011 Sep 15; 174(6):727-35.
    View in: PubMed
    Score: 0.087
  29. HIV quality performance measures in a large integrated health care system. AIDS Patient Care STDS. 2011 Jan; 25(1):21-8.
    View in: PubMed
    Score: 0.083
  30. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15; 49(10):1582-90.
    View in: PubMed
    Score: 0.077
  31. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis. 2009 Aug 01; 200(3):453-63.
    View in: PubMed
    Score: 0.076
  32. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis. 2005 Aug 01; 192(3):456-65.
    View in: PubMed
    Score: 0.057
  33. The Contribution of Socioeconomic Factors to HIV RNA Suppression in Persons With HIV Engaged in Care in the NA-ACCORD. J Acquir Immune Defic Syndr. 2024 Nov 01; 97(3):232-241.
    View in: PubMed
    Score: 0.054
  34. Evaluation of mean corpuscular volume among anemic people with HIV in North America following ART initiation. AIDS Res Ther. 2024 Aug 07; 21(1):52.
    View in: PubMed
    Score: 0.054
  35. Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America. J Acquir Immune Defic Syndr. 2021 05 01; 87(1):663-670.
    View in: PubMed
    Score: 0.043
  36. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open. 2021 02 01; 4(2):e2037512.
    View in: PubMed
    Score: 0.042
  37. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2551-9.
    View in: PubMed
    Score: 0.022
  38. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL. J Acquir Immune Defic Syndr. 2006 Sep; 43(1):56-9.
    View in: PubMed
    Score: 0.015

© 2024 Kaiser Permanente